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Abstract
OBJECTIVES: An orthotopic rat tumour recurrence model for malignant pleural mesothelioma (MPM) provides clinical similarity to
patients and is useful for drug testing combined with surgical intervention. Importantly, a reliable imaging method is required allowing for
noninvasive and repetitive evaluation of the tumour load. We compared the tumour load assessed by bioluminescence and magnetic res-
onance imaging (MRI) to the macroscopic tumour volume as a reference standard.
METHODS: A total of 500 000 syngeneic rat MPM cells transfected with luciferase were implanted underneath the parietal pleura of
immunocompetent rats (n = 13). From the second day after implantation, bioluminescence measurements of the tumour load expressed
as the maximum bioluminescent intensity (photon/second) were performed daily after intraperitoneal injection of the luciferase substrate,
D-luciferin, to observe the ﬁrst occurrence of tumour. Six days after the ﬁrst detection of tumour, bioluminescence, MRI and macroscopic
tumour volume measurement were conducted. For MRI, a 4.7-Tesla small animal imager equipped with a 1H whole-body rat coil was
employed using T2-weighted fast spin-echo sequences. Tumour burden (mm
3) was quantiﬁed from magnetic resonance transverse images
by two independent readers by manual segmentation. Finally, the tumour burden assessed by bioluminescence and MRI was correlated
(Pearson’s correlation) with the macroscopic measurement of tumour (ellipsoid) volume.
RESULTS: In all rats, a single tumour nodule was found at the inoculation site with a median macroscopic volume of 46 mm3 (18–377 mm3).
For tumour burden quantiﬁcation of MRIs, we observed good interobserver correlation (R2 = 0.81, P < 0.0001) as well as signiﬁcant associ-
ation with the macroscopic tumour volume (R2 = 0.59, P = 0.002). However, the signal intensity of bioluminescence did not correspond to
the macroscopic tumour volume (R2 = 0.01, P = 0.76).
CONCLUSIONS: MRI is a reliable and reproducible noninvasive in vivo imaging method for MPM tumour burden assessment for the
present MPMmodel.
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INTRODUCTION
Malignant pleural mesothelioma (MPM) is a rare and aggressive
tumour. The major cause of MPM is attributed to the inhalation of
asbestos ﬁbres into the lung causing chronic inﬂammation and
carcinogenesis. Although the use of asbestos in Europe was
banned in the 1980s, the incidence is expected to rise in the next
5–10 years because of long disease latency [1]. Currently, the most
widely used treatment approach includes a combination of
chemotherapy (cisplatin plus pemetrexed [2]) plus macroscopic
complete resection [3] with optional adjuvant radiotherapy [4].
Nonetheless, treatment response and long-term outcome are still
very variable (reviewed in [5]). Therefore, it is important to explore
novel targets as an alternative treatment option for MPM patients
not responding to current protocols.
Besides chemotherapy directed against proliferative tumour
cells, molecular targeted treatment and also immune therapy
have drawn major interest [6, 7]. Prior to clinical trials, efﬁciency of
new drug candidates have been tested in vitro using MPM primary
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cells or MPM human cell lines followed by preclinical animal
models. However, in vitro conditions cannot fully mimic the
tumour microenvironment that includes stromal cells, cytokines,
chemokine, blood and oxygen gradient which all together play a
major role in the growth, development and therapeutic resistance
of MPM. Thus, a reliable in vivomodel of MPM that closely resem-
bles the clinical situation is required for testing the efﬁcacy of new
drug candidates.
Many studies have relied on the use of a subcutaneous or
orthotopic xenograft immunodeﬁcient tumour model to test the
efﬁcacy of a new compound as well as its pharmacokinetics and
toxicities in vivo [8–11]. However, the immune system plays an
important role in tumour biology and may inﬂuence the regres-
sion of an MPM [12, 13]. Thus, an immunodeﬁcient animal model
cannot entirely represent the clinical situation.
Our group has established an orthotopic immunocompetent
rat model by implanting syngeneic rat mesothelioma cells (IL45)
underneath the parietal pleura, which regrows after surgical resec-
tion [14, 15]. This model was employed to test the efﬁcacy of a
multimodal treatment model combining surgery with intrapleural
cisplatin treatment or immunochemotherapy [15, 16]. However,
an in vivo, noninvasive imaging method is needed for reliable de-
tection and quantiﬁcation of the tumour burden. Fluorescence,
bioluminescence (Bli), computed tomography (CT) and magnetic
resonance (MR) have been employed for orthotopic MPM
tumour imaging [10, 11]. We created Bli-expressing clones of an
IL45 cell line (IL45-Luc) by stable transfection [17]. The implant-
ation of the IL45-Luc cells in an immune-competent rat generated
tumour masses that could be detected by the Bli imager as soon
as 3 days after inoculation. The IL45-Luc-derived tumour dis-
played the same histology as tumours derived from un-transfected
IL45 cells [17].
Discordance between Bli and the macroscopic tumour
volume measured was observed in some cases; therefore, we
implemented an MR imaging protocol in a small animal imager
as a third independent technique to assess the tumour burden.
Here, we present an approach to quantify tumour burden from
MR images. We investigated the correlation between the
tumour burden quantiﬁed from MR images and Bli signal with
the tumour volume measured macroscopically as a reference
standard.
MATERIALS ANDMETHODS
Tumour inoculation
The IL45-Luc cell line was maintained as previously described
[17]. Immunocompetent male Fischer 344 rats (n = 13) (F344/
NCrHsd; 200–250 g) were purchased from Harlan Laboratories
(the Netherland) and housed according to standard guidelines of
the Swiss animal health-care law. Experiments were approved by
the veterinary ofﬁce of Zürich. We inoculated 500 000 IL45-Luc
cells suspended in 50 µl of Dulbecco’s phosphate-buffered saline
underneath parietal pleura as previously described [17]. For anal-
gesia, all rats received paracetamol (30 mg/kg) 30 min before and
4 h after surgery.
Bli measurement began two days after inoculation, and contin-
ued daily until Bli signal appeared (n = 13). The ﬁrst Bli signals
were detected between 2 and 6 days after inoculation. After the
ﬁrst detection, tumours were grown for 6 days in order to avoid
>15% body weight loss. Seven rats received daily treatment of a
hedgehog antagonist which inhibits tumour cell proliferation by
10%, generating variation in tumour volume. Bli and MR imaging
were conducted prior to euthanization and the macroscopic
tumour volume measurement.
Bioluminescence imaging and the analysis
Animal preparation for Bli imaging was performed as previously
described [17]. Bli images were sequentially acquired with expos-
ure time of 60 s until the highest Bli signal was detected. We used
IVIS 200 living image software (Caliper Life Sciences, Inc., MA,
USA) to construct pseudo colour images of Bli signal overlaid on
the animal’s whole-body picture. A region of Bli [region of interest
(ROI)] was selected and quantiﬁed for area (mm2) and total Bli
signal (photon/second). Total Bli emission was plotted against
time after D-luciferin injection. The peak of Bli signal was taken for
analysis.
Magnetic resonance imaging and the
quantiﬁcation of tumour volume
Magnetic resonance imaging (MRI) was performed with a Bruker
4.7 T Pharmascan 47/16 US with a gradient strength of 375 mT/m
and a slew rate of 3375 T/ms. A linear polarized whole-body
mouse 1H radiofrequency coil was applied for spin excitation and
signal reception. During the scan, the rats were anaesthetized with
isoﬂurane (Attane; Minrad I, Buffalo, NY, USA). On-line respiration
monitoring was performed with an MR-compatible physiology
unit (SA Instruments, Inc., NY, USA). After gradient-echo localizers
in three spatial directions, the imaging protocol consisted of a 2D
encoded T2-weighted fast spin-echo sequence (TR/TE, 3528 ms/
11 ms; effective TE, 45 ms; echo train length, 8; matrix, 384 × 384;
ﬁeld of view, 60 × 60 mm2; slice thickness, 1 mm; number of
acquisitions, 5; interslice gap, 0.5 mm) in transverse, sagittal and
coronal orientation. After data acquisition, data sets were trans-
ferred to an off-line computer.
Two observers quantiﬁed tumour volume independently.
Image J software (Wayne Rasband, National Institutes of Health,
MD, USA) was used to deﬁne the tumour area on the T2-weighted
data set in transverse orientation by free hand drawing for each
slice depicting tumour tissue. Sagittal and coronal data sets were
opened in parallel to assist for tumour area identiﬁcation. Criteria
for tumour identiﬁcation were intermediate hyperintense signal
on T2-weighted imaging (hypointense to pleural effusion, hyperin-
tense to the anatomical thoracic wall, nodular masses, pleural
masses, whereas non-mass-like hyperintensity of the thoracic wall
was regarded as postinterventional changes caused by thoracot-
omy). In case tumour and scar tissues were indistinguishable, the
margin of the tumour was deﬁned at the middle of the rib. The
histological examination showed that the tumour never invaded
tissues behind the middle margin of the ribs. The tumour value
for each space between two image slices was calculated by the
formula
Volume ¼ ðArea1 þ Area2Þ  1:5 mm slice thickness
2
;
the complete tumour volume being obtained by integrating the
volumes of all slice intervals (see Fig. 1).
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Macroscopic tumour volume quantiﬁcation
After euthanasia with an overdose of pentobarbital and exsan-
guination, we excised the chest wall that contained the tumour
nodule. The length (a) and width (b) of the tumour were measured
with a slide callipers. The tumour area (mm2) was calculated by
the ellipsoid formula: area = π × a/2 × b/2. The thoracic wall was
cut at the thickest part and ﬁxed in formalin for histological
analysis. The thickness of tumour (c) was measured on the H&E
section. Finally, the tumour volume was approximated using the
ellipsoid formula: V = 4/3 π × a/2 × b/2 × c/2 [15].
Histology and proliferation index
Tissues were ﬁxed in 4% formalin for 24 h and then de-calciﬁed in
EDTA solution for 2–3 weeks. Afterwards, they were intensively
washed in water, dehydrated in a series of alcohol solutions and
embedded in parafﬁn. Tissues were cut at 3 μm thickness and
stained for H&E and collagen using the Sirius red method. The
proliferation index with Ki67 (rabbit anti-Ki-67, CMC27531021;
Cell Marque) was quantiﬁed as the percentage of positive Ki67
tumour nuclei per total tumour nuclei [18].
Statistical analysis
Statistical analysis has been performed by computation of Pearson’s
correlation coefﬁcient using Prism 5 (GraphPad software, Inc., CA,
USA). A P value of less than 0.05 was considered signiﬁcant. The
intraclass correlation coefﬁcient was computed by SPSS 22.
RESULTS
Characteristics of IL45-Luc-derived tumour
At autopsy (6 days after the ﬁrst tumour detection), a single tumour
nodule was visible at the injection site (Fig. 2A) in all rats with a
median macroscopic tumour volume of 46 mm3 (range; 18–377 mm3,
Supplementary Table 1). As described previously, tumours
derived from IL45-luc were of the sarcomatoid mesothelioma
subtype (Fig. 2B). The stromal compartment including ﬁbroblasts,
immune cells, extracellular matrix and vessels was present (Fig. 2B
and C). Tumours were highly proliferative as shown by the over
70% Ki-67 staining index (Fig. 2D), and the tumours were without
any necrotic area.
Bioluminescence imaging
The median maximum Bli signal was observed at 21.5 min (range;
16–32 min) after injection of D-luciferin with the median bio-
luminescent value of 1.21 × 107 p/s (range; 3.6 × 106–4.9 × 107 p/s,
Supplementary Table 1). We observed postoperative inﬂammation
localized at the thoracotomy site in some rats and reduced bio-
luminescence signal within this area (data not shown). Tumour
areas (2D) quantiﬁed from Bli were 30 times (range; 12–45 times)
Figure 1: Diagram showing tumour volume quantiﬁcation from MR images.
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larger than the actual macroscopic tumour area but showed a
trend of positive correlation (R2 = 0.22, P = 0.1) (Fig. 3A). However,
the total tumour burden quantiﬁed from the Bli image (photon/
second) did not correlate with macroscopic tumour volume
(Fig. 6B).
Magnetic resonance images
Tumour nodules appeared within 5–14 image sections, showing
irregular shape. Tumour and postoperative scar were visible
as slightly hyperintense signals compared with the chest wall,
Figure 2: (A) Macroscopic appearance of a tumour derived from IL45-Luc cells. A white tumour nodule is found around the injection site. (B) In an H&E staining and
indicated by arrow; tumour cells (T), stromal part containing blood vessels (V), lymphocytes (L) and ﬁbroblasts (F). (C) Collagen staining showing the presence of colla-
gen bundles (red) inﬁltrates. (D) Ki67 staining (brown) of tumour cells.
Figure 3: (A) A trend of positive correlation between tumour area quantiﬁed in Bli images and macroscopically (n = 13). (B) Example of Bli image of a rat (ROI: region
of interest).
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whereas strong hyperintensity represents areas of inﬂammation or
ﬂuid collections (Fig. 4A). The correlation of tumour volume mea-
sured from MR images by the two observers was highly signiﬁcant
with a Pearson correlation coefﬁcient of 0.81 (Fig. 4B) and intra-
class correlation coefﬁcient of 0.903. For the further analyses, the
average of tumour volumes quantiﬁed by the two observers was
used. The median tumour burden quantiﬁed from MR images was
145.4 mm3 (range; 77.7–609.8 mm3, Supplementary Table 1) and
was 3.5 (median) times higher than the one measured macroscop-
ically (range; 0.7–7.6 times). We could not observe any correlation
between tumour burden quantiﬁed from MR images and total Bli
signal (Fig. 5A and B). However, tumour volume measured macro-
scopically and fromMRI images correlated signiﬁcantly (Fig. 6A).
Discussion
Our orthotopic immune-competent rat MPM model provides a
tumour microenvironment that closely reﬂects the clinical situ-
ation. It was proved useful for testing new drug candidates as well
as surgical intervention and will provide greater beneﬁt if the
tumour can be monitored repetitively and noninvasively. MR
imaging and Bli were assessed for their reliability in tumour
burden quantiﬁcation by comparing with the macroscopic
tumour volume. In this study, we found that MR imaging provides
more reliable tumour burden assessment than Bli as it correlates
strongly with the macroscopic tumour volume. Quantiﬁcation of
tumour burden from MR images is a reliable approach as the
measurements can be reproduced independently by two obser-
vers. MR imaging has been successfully applied for the visualiza-
tion of MPM in the orthotopic mouse model of MPM as well as
other models of solid tumours [10, 19].
The quantiﬁcation of tumour volume from MR images was feas-
ible and reproducible (good interobserver agreement). Nevertheless,
we observed that ﬁbrous postoperative scar interferes with the quan-
tiﬁcation of tumour volume from MR images. A possible solution for
the discrimination between tumour and the postoperative changes
including inﬂammation and ﬁbrosis might be the use of ‘diffusion-
weighted imaging’ (DWI). ‘Apparent diffusion coefﬁcient’ values,
which are commonly used to quantify the results of DWI, are
described as the speciﬁc parameter for the differentiation of recur-
rence of tumour and scar in breast cancer [20]. However, the role of
DWI in the differentiation of mesothelioma from postoperative
changes is hitherto unknown. Furthermore, an impeded diffusion
that is seen in tumours can also be seen in inﬂammatory or infected
areas due to the increased cellular density in those areas [21].
Therefore, DWI might be an interesting tool for the differentiation of
tumours and postoperative changes in the future, but the potential
Figure 4: (A) Example of MR images (transverse/coronal/sagittal); the margins of tumour area are indicated with yellow lines. (B) Signiﬁcant correlation of tumour
volumes quantiﬁed in transverse images by two independent observers (n = 13).
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application for mesothelioma needs to be evaluated. Furthermore, a
semi-automated approach has been successfully applied for the
measurement of MPM tumour thickness in CT scan images [22]. A
computer interface requires users to indicate an initial end-point;
thereafter, it determines the corresponding terminal end-point auto-
matically using a greyscale threshold. It showed high agreement with
manual quantiﬁcation and thus may also be applicable for tumour
volume quantiﬁcation fromMR images that we acquired.
The tumour volume obtained from MR images was about
two times bigger than the volume quantiﬁed macroscopically.
This systemic positive bias could be explained by continuous
underestimation of tumour thickness measured from H&E sec-
tions due to shrinkage of tissues after a ﬁxation and dehydration
procedure. Indeed the thickness of the tumour measured from
MR images was larger than the thickness measured from H&E sec-
tions (data not shown).
Figure 5: (A) Scatter plot between tumour volume quantiﬁed from MR images and Bli signal showing no correlation (n = 13). (B) Images showing typical discrepancies
between tumour volume visualized by MR and Bli signal. Rat 2 shows strong Bli signal (red); however, the tumour size visible by MRI is smaller than that of Rat 1,
which exhibited lower Bli intensity.
Figure 6: Correlation between macroscopic tumour volume versus MRI and Bli: (A) Positive correlation between tumour volume quantiﬁed from MR images (mm3)
(average of two observers) and macroscopic tumour volume. (B) Bli signal (photon/second) does not correlate with macroscopic tumour volume.
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Several studies in subcutaneous or intraperitoneal tumour
models showed strong correlation between Bli and actual tumour
volume [23, 24]. In our study, 2D analyses (tumour area) of both Bli
and macroscopic observation show only a trend of positive correl-
ation; this may be explained by the small sample size. However,
tumour areas visualized in Bli images were overestimated prob-
ably due to the inclusion of light radiance. Total bioluminescent
emission (3D) correlates with neither the macroscopic tumour
volume nor MRI tumour burden. This discordance between Bli
and tumour volume can be explained by several reasons. The
emission of Bli signal depends on the extent of luciferase expres-
sion and the penetration depth of light [25]. In our model, tumour
nodules were deeply embedded in the thoracic cavity. In some
cases, Bli can be hindered near the operation site by tissue thick-
ening that results from inﬂammation and postoperative scar.
Accurate injection of D-luciferin into the intraperitoneal cavity is
crucial as, in some cases, no Bli signal was detected after injection.
Upon re-injection of D-luciferin into the same rat, Bli signal
appeared immediately. Intravenous administration may be a
better method for applying the correct dosage of D-luciferin;
however, it is practically difﬁcult to inject sequentially large
volumes of substrate intravenously in rats (authors’ own experi-
ence). There are different types of information obtained from Bli
signal versus total tumour volume. Bli signal can only be emitted
from living tumour cells and therefore indicates the burden of
tumour cells alone, excluding apoptotic and necrotic cells. It is a
sensitive detection method and is suitable for early detection of
tumour growth after testing a compound that causes necrosis and
apoptosis. However, Bli signal does not include the stromal frac-
tion. Total tumour volume can be represented by MR images and
macroscopic observations. Thus, the combination of the two
methods may provide an advantage and distinguish the effect of
drugs on the stromal compartment.
Disadvantages of the MR examination are that they are relative-
ly costly examinations due to the purchasing costs and the main-
tenance of the MR imager. The duration of MR image acquisition
varied from 45 min to 1 h per rat, hence increasing anaesthesia
and experimental duration. In principle, metals could be a
problem, e.g. implanted material after surgery, due to the propen-
sity of these materials to cause distortions of the magnetic ﬁeld.
However, the material used in this study did not cause relevant
image artefacts. On the other hand, Bli provides a faster imaging
method as two rats can be placed in the Bli imaging chamber and
measured simultaneously for a maximum of 35 min. However, a
big volume of D-luciferin is required for a rat weighting between
250 and 300 g and the injection caused stress especially in repeti-
tive measurements.
In our speciﬁc orthotopic rat MPM model, MR imaging provided
more reliable tumour burden quantiﬁcation. However, the mea-
surements in rats were hindered by the postoperative scar and
inﬂammation, which are common problems that impede tumour
mass detection in humans. This model will be further deﬁned to
better discriminate between tumour and postoperative scar. In our
study, a small thoracotomy was performed for tumour inoculation
and we observed that the scar tissue and inﬂammation was dimin-
ishing over the recovery time of 6 days. By inoculating fewer
tumour cells, the duration of the experiment may be extended to
allow healing and recovery from inﬂammation before the assess-
ment. These imaging techniques may be applied for tumour load
assessment following major surgery such as radical pleurectomy
and extrapleural pneumonectomy; however, proper recovery time
needs to be validated. Moreover, contrast medium for MR imaging
will be tested for its potential application to discriminate tumour
from scar. Advances in the development of imaging methods for
such orthotopic preclinical animal models will represent great pro-
gress in the ﬁeld of cancer research for therapeutic development.
SUPPLEMENTARYMATERIAL
Supplementary material is available at EJCTS online.
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